The latest at MBC Biolabs
The latest at MBC Biolabs
Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study
Siolta initiates dosing in newborn subjects in a groundbreaking trial of STMC-103H
Switch Bioworks Raises $4.3M to Feed a Growing World Sustainably
Next-generation biofertilizer startup sets out to tackle climate change with synthetic biology and microbes.
MBC BioLabs Announces New Partnership with Benchling
Benchling’s R&D Cloud makes it easier to capture and access the data you need, collaborate as a team, and accelerate decision making.
MBC BioLabs is Excited to Welcome Shimadzu as its Newest Partner
Shimadzu's Nexera Prep HPLC System is available at MBC BioLabs @ 930 Brittan.
AbbVie Golden Ticket Winners 2022
Qinotto and Think Bioscience are the winners of the AbbVie 2022 Golden Ticket Competition.
ONO Golden Ticket 2022
Apply until May 6!
AbbVie Golden Ticket 2022
Apply until February 18
Dren Bio Announces Research Collaboration and License Agreement with Pfizer
Dren Bio received $25 million upfront payment as part of overall deal for selected oncology targets that includes over $1 billion in potential cash payments plus potential future product-based sales royalties
AbbVie Golden Ticket Winners 2021
Regel Therapeutics and Weatherwax Bio are the winners of the "AbbVie 2021 Golden Ticket Competition".
Astellas and MBC BioLabs Announce Future Innovator Prize Winners
Vcreate and Weatherwax Biotechnologies win a year of access to life-science incubator in San Francisco, CA and to Astellas expertise to further their research.
Eisai Innovation, Inc. Golden Ticket 2021 Winner
Deciduous Therapeutics was selected as the winner of the 2021 Eisai Golden Ticket Competition
Eisai and MBC BioLabs Announce Winner of Golden Ticket Competition
Eisai and MBC BioLabs Announce Winner of Golden Ticket Competition to Support Biotech Start-ups Accelerate Early Drug Discovery
Astellas and MBC BioLabs Announce Future Innovator Prize
Astellas and MBC BioLabs announce their third collaboration on the "Future Innovator Prize" formerly known as Astellas Golden Ticket.
Eisai Innovation, Inc. Golden Ticket 2021
Eisai Innovation and MBC BioLabs Announce 2021 Eisai Golden Ticket Competition to Accele [...]
MBC BioLabs welcomes Eisai Innovation, Inc. as our newest partner
MBC BioLabs is thrilled to announce our latest partner is Eisai Innovation, Inc. (EII), an affiliate of Eisai Co., Ltd. the fully integrated pharmaceutical company based in Tokyo, Japan.
Bristol Myers Squibb Golden Ticket 2021
Apply now for one year free bench space!
Revel Pharmaceuticals revels in new Agilent program
Revel has tapped the Agilent Instrument Subscriptions Program to gain access to a mass spectrometer, critical in the startup’s work to combat the damages of aging.
Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures
Soteria, a privately-held, immuno-oncology company focused on developing a next generation of switchable bispecific T-cell engagers to treat patients with solid tumor cancers, announces $42 Million Series A Financing.
Alessa Therapeutics Announces First Australian Patient Enrolled in Biolen-PC Study for Localized Drug Delivery for Prostate Cancer
Alessa Therapeutics announces the enrollment of the first patient in their clinical study in Australia. The Biolen-PC study will treat up to 20 patients in Australia and New Zealand.
Fujifilm Joins MBC Biolabs as Sponsor to Foster Innovation in Biotech
MBC BioLabs is excited to announce a strategic partnership with Fujifilm Open Innovation Hub to support biotech collaboration and innovation in our startup ecosystem.
Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie
AbbVie, a leading global biopharmaceutical company, has purchased an exclusive right to acquire Mitokinin following completion of IND enabling studies on Mitokinin's lead PINK1 compound.
ONO Entered Sponsorship Agreements with MBC BioLabs and LabCentral
This sponsorship will allow ONO to early access the most updated information of the biotech startups and others residing in LabCentral and MBC BioLabs facilities.
Cage Bio closes $7.2 million round of series A funding
The investment was led by professional and angel investor groups consisting of current and former pharmaceutical executives and physicians.
BigHat Biosciences Raises $19 Million in Series A Funding
BigHat Biosciences, a novel protein therapeutics company and developer of an AI-guided antibody design platform, announced it has raised $19 million in an oversubscribed Series A funding round.